Glimpsing the future: New immune-based therapies for multiple myeloma.


Over the last year, the U.S. FDA approved a flurry of new drugs for use in multiple myeloma, a cancer that affects the bone marrow. Those drugs, seven in total, represent a near doubling of the drugs approved throughout the last 12 years to treat the disease.

“There’s now a very good understanding of the mechanisms we need to target to interrupt multiple myeloma cell growth, survival, and resistance,” explains Kenneth Anderson, director of the Jerome Lipper Multiple Myeloma Center and the LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute.

View PDF